Clinical Trials Logo

Prostate Cancer clinical trials

View clinical trials related to Prostate Cancer.

Filter by:
  • Not yet recruiting  
  • Page 1 ·  Next »

NCT ID: NCT03802851 Not yet recruiting - Prostate Cancer Clinical Trials

HoLEP Prior to Radiation Therapy for Patients With LUTS/Retention and Concurrent Prostate Cancer

Start date: April 2019
Phase: N/A
Study type: Interventional

To determine if holmium laser enucleation of the prostate (HoLEP) for the treatment of lower urinary tract symptoms (LUTS) and/or urinary retention alters the treatment course for patients concurrently diagnosed with prostate cancer.

NCT ID: NCT03800784 Not yet recruiting - Prostate Cancer Clinical Trials

Study of 18F-DCFPyL PET/CT Imaging in Patients With Prostate Cancer

Start date: January 15, 2019
Phase: Phase 2/Phase 3
Study type: Interventional

This study evaluates the rate of radiological disease progression with the new 2nd generation positron emission tomography (PET) radiopharmaceutical, 18F-DCFPyL, in patients with metastatic castration (mCRPC) and non-metastatic (nmCRPC) castration resistant prostate cancer who have evidence of biochemical (PSA) disease progression without evidence of radiological disease progression on conventional standard radiologic testing (99mTc-methylene diphosphonate bone scan and CT).

NCT ID: NCT03796195 Not yet recruiting - Prostate Cancer Clinical Trials

(SGB) in Men Treated for Prostate Cancer Improve Hot Flashes

Start date: February 15, 2019
Phase: Phase 4
Study type: Interventional

Androgen Deprivation Therapy (ADT) is a critical component of advanced prostate cancer treatment but causes numerous adverse effects including decreased bone mass, decreased muscle mass, gynecomastia, erectile dysfunction, loss of sexual desire, depression, disordered sleep, urinary symptoms, and hot flashes (HF). HF are unpleasant paroxysmal episodes of flushing, sweating with vasodilation of the face, neck, and chest. These episodes can last for seconds to minutes and are often associated with night sweats, anxiety, and insomnia and have negative effects on quality of life. Stellate ganglion blockade (SGB) with local anesthetic may be an effective treatment of HF in men on ADT, but has not been studied in any published clinical trials. The stellate ganglion is a neural structure in the anterior cervical spine region and is part of the sympathetic nervous system. It has been injected safely in the practice of pain management for more than 50 years in cases of post herpetic neuralgia (shingles), complex regional pain syndrome (CRPS) and other painful neuropathies as well as some types of cardiac dysrhythmias. Given the frequency and severity and interference of HF in men on ADT for prostate cancer, in addition to the negative effects HF impose on this patient population and a paucity of effective treatments, finding alternative treatments for HF in this population is needed.

NCT ID: NCT03795337 Not yet recruiting - Prostate Cancer Clinical Trials

Hypofractionated Radiosurgery for Localised Prostate Cancer (HYPOSTAT-II)

Start date: January 2019
Phase: N/A
Study type: Interventional

Hypofractionated radiosurgery has been investigated in a few trials and appears to be safe and feasible. Investigators initiated this multicenter phase II prospective trial to analyse feasibility (toxicity) of hypofractionated radiosurgery with 5 fractions in patients with localised prostate cancer under the hypothesis that the ratio of patients with late toxicity ≥ grade 2 after 3 years amounts 4.1% and is significant lower than 12.3% and 8.7% currently.

NCT ID: NCT03793543 Not yet recruiting - Prostate Cancer Clinical Trials

Test-Retest Reproducibility of 18F-DCFPyL PET/CT in the Evaluation of Patients With Metastatic Prostate Cancer

Start date: January 2019
Phase: Phase 1
Study type: Interventional

In this study, the investigators intend to validate 18F-DCFPyL test-retest reproducibility in metastatic lesions, in order to investigate whether it serves as a reliable response assessment tool, both to interpret existing studies and to design future longitudinal trials.

NCT ID: NCT03792841 Not yet recruiting - Prostate Cancer Clinical Trials

Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 160 in Subjects With mCRPC

Start date: February 15, 2019
Phase: Phase 1
Study type: Interventional

A study to evaluate the safety and tolerability of AMG 160 in adult subjects with metastatic castration-resistant prostate cancer (mCRPC), and determine the maximum tolerated dose (MTD) or recommended phase 2 dose (RP2D).

NCT ID: NCT03787680 Not yet recruiting - Prostate Cancer Clinical Trials

Targeting Resistant Prostate Cancer With ATR and PARP Inhibition (TRAP Trial)

Start date: February 2019
Phase: Phase 2
Study type: Interventional

The purpose of this study is to test the effectiveness (how well the drugs work), safety, and tolerability of the investigational drug combination of olaparib and AZD6738 for all patients with metastatic castration-resistant prostate cancer.

NCT ID: NCT03786848 Not yet recruiting - Prostate Cancer Clinical Trials

Personalized Mini-PDX for Metastatic CRPC

Start date: December 26, 2018
Phase: N/A
Study type: Interventional

The investigators intend to use the Second-generation sequencing(NGS)and MiniPDX drug sensitivity models to guide the treatment decision-making for patients who were resistant to abiraterone, enzalutamide or other new second-generation anti-androgenic drugs. In order to develop precise personalized treatment plans for patients and extent their lifetimes.

NCT ID: NCT03784924 Not yet recruiting - Prostate Cancer Clinical Trials

EDRN Prostate MRI Biomarker Study

Start date: January 2, 2019
Study type: Observational

The commercialization of MRI fusion biopsies has resulted in a dramatic increase in the use of MRI imaging for prostate cancer. How best to use MRI in the initial prostate biopsy setting given the availability of validated prostate cancer early detection markers is uncertain.This study will allow investigators to determine if prostate MRI is superior to validated panel of laboratory biomarkers (e.g. PCA3, PSA and TMPRSS2:ERG) in the initial biopsy setting.

NCT ID: NCT03777982 Not yet recruiting - Prostate Cancer Clinical Trials

A Randomized Phase III Study - Conventional ADT w/ or w/Out Abiraterone Acetate + Prednisone and Apalutamide Following a Detectable PSA After Radiation and ADT

Start date: January 30, 2019
Phase: Phase 3
Study type: Interventional

This research study is being offered to those patients who have already received radiation therapy and who are receiving long-term hormonal therapy for their prostate cancer and whose PSA remains detectable (greater than 0.1) despite having received at least 6, but no more than 8 months of hormonal therapy. The name of the study drugs involved in this study is: - LHRHA (luteinizing hormone-releasing hormone agonist or antagonist) - Abiraterone Acetate - Apalutamide - Prednisone